MedTrace Logo

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

NCT00408330 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-06-09

No results posted yet for this study

Summary

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

Conditions

  • Seborrheic Dermatitis on the Face

Interventions

DRUG

Azelaic Acid 15% Gel

15% gel, topically applied daily for six weeks

DRUG

Inactive 15% gel base

placebo, topically applied daily for six weeks

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408330 on ClinicalTrials.gov